|By PR Newswire||
|September 5, 2014 07:30 AM EDT||
PITTSBURGH, Sept. 5, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has launched Ibandronate Sodium Injection, 1 mg (base)/mL, packaged in 3 mg (base)/3 mL pre-filled glass syringes, which is the generic version of Hoffmann-La Roche's Boniva® Injection. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of osteoporosis in postmenopausal women.
Ibandronate Sodium Injection, 1 mg (base)/mL, packaged in 3 mg (base)/3 mL pre-filled glass syringes had U.S. sales of approximately $18.4 million for the 12 months ending June 30, 2014, according to IMS Health.
Currently, Mylan has 288 ANDAs pending FDA approval representing $110.3 billion in annual brand sales, according to IMS Health. Forty-two of these pending ANDAs are potential first-to-file opportunities, representing $27.5 billion in annual brand sales, for the 12 months ending June 30, 2014, according to IMS Health.
Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,300 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com
SOURCE Mylan Inc.
In today's uber-connected, consumer-centric, cloud-enabled, insights-driven, multi-device, global world, the focus of solutions has shifted from the product that is sold to the person who is buying the product or service. Enterprises have rebranded their business around the consumers of their products. The buyer is the person and the focus is not on the offering. The person is connected through multiple devices, wearables, at home, on the road, and in multiple locations, sometimes simultaneously...
Jul. 31, 2016 01:30 AM EDT Reads: 989
Jul. 31, 2016 12:45 AM EDT Reads: 2,041
Jul. 30, 2016 11:30 PM EDT Reads: 1,338
Jul. 30, 2016 10:30 PM EDT Reads: 1,944
Jul. 30, 2016 09:45 PM EDT Reads: 1,497
Jul. 30, 2016 09:45 PM EDT Reads: 1,320
Jul. 30, 2016 09:30 PM EDT Reads: 1,533
Jul. 30, 2016 07:30 PM EDT Reads: 1,768
Jul. 30, 2016 07:30 PM EDT Reads: 1,320
Jul. 30, 2016 07:00 PM EDT Reads: 2,777
Jul. 30, 2016 05:00 PM EDT Reads: 1,311
Jul. 30, 2016 04:30 PM EDT Reads: 588
Jul. 30, 2016 04:30 PM EDT Reads: 1,128
Jul. 30, 2016 04:30 PM EDT Reads: 2,283
Jul. 30, 2016 04:15 PM EDT Reads: 661